Premium
Signet‐ring cell carcinoma of the prostate effectively treated with maximal androgen blockade
Author(s) -
AKAGASHI KEIGO,
TANDA HITOSHI,
KATO SHUJI,
OHNISHI SHIGEKI,
NAKAJIMA HISAO,
NANBU AKIHITO,
NITTA TOSHIKAZU,
KOROKU MIKIO
Publication year - 2003
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2003.00649.x
Subject(s) - medicine , signet ring cell carcinoma , blockade , prostate , rectum , androgen , urology , adjuvant therapy , oncology , carcinoma , adjuvant , medical therapy , adenocarcinoma , chemotherapy , cancer , receptor , hormone
Primary signet‐ring cell carcinoma (SRCC) of the prostate is very rare and has a poor prognosis, even when treated with aggressive therapy. We report herein a case of a 72‐year‐old man with prostatic SRCC. The patient had a tumor that extended directly to the rectum. Maximal androgen blockade was started and 20 months later, the patient was alive without evidence of recurrence. The present case of prostatic SRCC responded well to medical therapy, however, tumors can recur after a long period of time. Therefore, adjuvant therapy is recommended.